Coût annuel de la prise en charge par biothérapie dans la polyarthrite rhumatoïde en 2011: Une question d'importance pour le rhumatologue
Identifieur interne : 000691 ( France/Analysis ); précédent : 000690; suivant : 000692Coût annuel de la prise en charge par biothérapie dans la polyarthrite rhumatoïde en 2011: Une question d'importance pour le rhumatologue
Auteurs : Milka Maravic [France] ; Isabelle Bru [France]Source :
- Rhumatos [ 1771-0081 ] ; 2011.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Hospitalisation.
English descriptors
- KwdEn :
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000135
- to stream PascalFrancis, to step Curation: 000129
- to stream PascalFrancis, to step Checkpoint: 000128
- to stream Main, to step Merge: 003C02
- to stream Main, to step Curation: 003B63
- to stream Main, to step Exploration: 003B63
- to stream France, to step Extraction: 000691
Links to Exploration step
Pascal:11-0466646Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="fr" level="a">Coût annuel de la prise en charge par biothérapie dans la polyarthrite rhumatoïde en 2011: Une question d'importance pour le rhumatologue</title>
<author><name sortKey="Maravic, Milka" sort="Maravic, Milka" uniqKey="Maravic M" first="Milka" last="Maravic">Milka Maravic</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hôpital Bellan, Département d'Information Médicale</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>3M CONSEILS</s1>
<s2>75019 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bru, Isabelle" sort="Bru, Isabelle" uniqKey="Bru I" first="Isabelle" last="Bru">Isabelle Bru</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Pharmacien, UCB Pharma SA</s1>
<s2>Colombes</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Colombes</wicri:noRegion>
<wicri:noRegion>UCB Pharma SA</wicri:noRegion>
<wicri:noRegion>Colombes</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0466646</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0466646 INIST</idno>
<idno type="RBID">Pascal:11-0466646</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000135</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000129</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000128</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000128</idno>
<idno type="wicri:doubleKey">1771-0081:2011:Maravic M:cout:annuel:de</idno>
<idno type="wicri:Area/Main/Merge">003C02</idno>
<idno type="wicri:Area/Main/Curation">003B63</idno>
<idno type="wicri:Area/Main/Exploration">003B63</idno>
<idno type="wicri:Area/France/Extraction">000691</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="fr" level="a">Coût annuel de la prise en charge par biothérapie dans la polyarthrite rhumatoïde en 2011: Une question d'importance pour le rhumatologue</title>
<author><name sortKey="Maravic, Milka" sort="Maravic, Milka" uniqKey="Maravic M" first="Milka" last="Maravic">Milka Maravic</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hôpital Bellan, Département d'Information Médicale</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>3M CONSEILS</s1>
<s2>75019 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bru, Isabelle" sort="Bru, Isabelle" uniqKey="Bru I" first="Isabelle" last="Bru">Isabelle Bru</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Pharmacien, UCB Pharma SA</s1>
<s2>Colombes</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Colombes</wicri:noRegion>
<wicri:noRegion>UCB Pharma SA</wicri:noRegion>
<wicri:noRegion>Colombes</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Rhumatos</title>
<title level="j" type="abbreviated">Rhumatos</title>
<idno type="ISSN">1771-0081</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Rhumatos</title>
<title level="j" type="abbreviated">Rhumatos</title>
<idno type="ISSN">1771-0081</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abatacept</term>
<term>Adalimumab</term>
<term>Anakinra</term>
<term>Antineoplastic agent</term>
<term>Antipsoriatic agent</term>
<term>Antirheumatic agent</term>
<term>Biotherapy</term>
<term>Certolizumab pegol</term>
<term>Chronic</term>
<term>Costs</term>
<term>Etanercept</term>
<term>Hospitalization</term>
<term>Immunomodulator</term>
<term>Immunosuppressive agent</term>
<term>Infliximab</term>
<term>Rheumatoid arthritis</term>
<term>Rituximab</term>
<term>Tocilizumab</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Polyarthrite rhumatoïde</term>
<term>Biothérapie</term>
<term>Abatacept</term>
<term>Adalimumab</term>
<term>Coût</term>
<term>Hospitalisation</term>
<term>Anakinra</term>
<term>Certolizumab pégol</term>
<term>Etanercept</term>
<term>Infliximab</term>
<term>Rituximab</term>
<term>Tocilizumab</term>
<term>Chronique</term>
<term>Immunomodulateur</term>
<term>Antipsoriasique</term>
<term>Immunodépresseur</term>
<term>Anticancéreux</term>
<term>Antirhumatismal</term>
<term>Prise en charge</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Hospitalisation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
</settlement>
</list>
<tree><country name="France"><region name="Île-de-France"><name sortKey="Maravic, Milka" sort="Maravic, Milka" uniqKey="Maravic M" first="Milka" last="Maravic">Milka Maravic</name>
</region>
<name sortKey="Bru, Isabelle" sort="Bru, Isabelle" uniqKey="Bru I" first="Isabelle" last="Bru">Isabelle Bru</name>
<name sortKey="Maravic, Milka" sort="Maravic, Milka" uniqKey="Maravic M" first="Milka" last="Maravic">Milka Maravic</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000691 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000691 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= TocilizumabV1 |flux= France |étape= Analysis |type= RBID |clé= Pascal:11-0466646 |texte= Coût annuel de la prise en charge par biothérapie dans la polyarthrite rhumatoïde en 2011: Une question d'importance pour le rhumatologue }}
This area was generated with Dilib version V0.6.34. |